A number of CTAs including SCP1, MAGE, SPAN‐Xb, SLLP1 and PRAME CTAs have been identified in unmanipulated AML blasts and may correlate with an improved overall survival.13, 14, 15 In the RAAVA Phase II trial patients, we showed that azacitidine and vorinostat increased expression of a number of CTAGs not previously reported such as LAGE, TRAG3 and SART3. The gene discussed is PRAME; the disease is acute myeloid leukemia.